Global retailer TK Maxx revealed as anchor for historic Geelong CBD redevelopment

A major American retailer with more than 600 stores globally will be the anchor tenant in the Bright and Hitchcocks building in central Geelong that is being redeveloped by the Hamilton Group.

Could Germany adopt AI giant Anthropic?

After Donald Trump ordered the US government to cancel all contracts with Anthropic, a German politician has said Germany should offer to bring the AI firm to Europe. The US government's decision to ...
Finanznachrichten

T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors

-Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation SAN FRANCISCO and BERLIN, March 03, 2026 (GLOBE NEWSWIRE) -- T-knife ...
Mena FN

T-Knife Therapeutics Announces Authorization Of Clinical Trial Application For TK-6302, A Multi-Armored, CRISPR Based T Cell Therapy For Solid Tumors

(MENAFN- GlobeNewsWire - Nasdaq) - Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation SAN FRANCISCO and BERLIN, March 03, 2026 ...
Santé log

T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors

SAN FRANCISCO and BERLIN, March 03, 2026 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing next-generation T cell therapies to fight cancer, today announced the ...
STAT

Prasad overruled FDA staff to reject Moderna’s flu vaccine application

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — Top Food and Drug ...
NPR

Head Start centers told to avoid 'disability,' 'women' and more in funding requests

Some Head Start early childhood programs are being told by the federal government to remove a list of nearly 200 words and phrases from their funding applications or they could be denied. That's ...
BioSpace

T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy

-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need - ...